Product image of Liamid (Glibenclamide) supplied by GNH India

Liamid

Active Ingredient:
Glibenclamide
Origin:
EU

Liamid (Glibenclamide)

Glibenclamide, the active ingredient in Liamid, is a second‑generation sulfonylurea presented as an oral tablet for oral administration. It acts by enhancing insulin secretion from pancreatic β‑cells, thereby reducing elevated blood glucose levels. Liamid is indicated for the treatment of type 2 diabetes mellitus in adult patients requiring oral hypoglycemic therapy.

GNH India supplies Liamid as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with distribution channels aligned to EU regulatory standards. The company ensures product quality through rigorous testing and adherence to Good Manufacturing Practices.

Manufacturer / TM Owner

Milpharm Limited

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Liamid (glibenclamide) is used within the sulfonylurea class to improve glycaemic control in patients with type 2 diabetes mellitus.

  • Type 2 diabetes mellitus (adult): lowers fasting and post‑prandial glucose by stimulating insulin release.
  • Hyperglycaemia secondary to type 2 diabetes: helps achieve target HbA1c levels when diet and exercise are insufficient.
  • Adjunct to diet and exercise in type 2 diabetes: provides additional glucose‑lowering effect alongside lifestyle measures.

How It Works

  • Glibenclamide binds to the sulfonylurea receptor subunit of the ATP‑sensitive potassium channel on pancreatic β‑cells, causing channel closure. This depolarises the cell membrane, opens voltage‑dependent calcium channels, and increases intracellular calcium, which triggers exocytosis of insulin granules, thereby raising circulating insulin levels and reducing blood glucose.

Side Effects

Common Side Effects

  • Hypoglycaemia: feeling of shakiness, sweating, or confusion due to low blood sugar.
  • Weight gain: modest increase in body weight associated with improved glycaemic control.
  • Nausea or abdominal discomfort: mild gastrointestinal upset.
  • Skin rash or pruritus: mild dermatologic reactions.
  • Headache: transient head discomfort.

Serious or Rare Side Effects

  • Severe hypoglycaemia: can lead to loss of consciousness or seizures.
  • Allergic reactions such as Stevens‑Johnson syndrome or toxic epidermal necrolysis.
  • Hemolytic anaemia or other blood dyscrasias.
  • Hepatic dysfunction: elevated liver enzymes or jaundice.
  • Cardiovascular events in susceptible patients.

Precautions & Warnings

Before initiating therapy, consider the following precautions:

  • Monitor blood glucose regularly: adjust dose based on glycaemic response.
  • Adjust dose in renal impairment: reduced clearance may increase risk of hypoglycaemia.
  • Use caution in elderly patients: increased sensitivity to insulin‑secretagogue effects.
  • Avoid in patients with known sulfonylurea hypersensitivity: risk of severe allergic reactions.
  • Pregnancy and lactation: safety not established, consult a physician before use.
  • Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Avoid Interactions

Glibenclamide may interact with several medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid)

  • Concomitant use with insulin or other sulfonylureas: markedly increased risk of severe hypoglycaemia.
  • Strong CYP2C9 inhibitors (e.g., fluconazole, amiodarone): may raise glibenclamide plasma levels, leading to toxicity.

Moderate Interactions (Monitor Closely)

  • CYP2C9 inducers (e.g., rifampicin, carbamazepine): may reduce drug efficacy.
  • Thiazide diuretics: can attenuate glucose‑lowering effect and increase blood pressure.
  • NSAIDs or ACE inhibitors: may affect renal function, altering glibenclamide clearance.

Frequently Asked Questions

Liamid contains glibenclamide, a second‑generation sulfonylurea that is prescribed to improve blood‑sugar control in adults with type 2 diabetes mellitus when diet, exercise, or other oral agents are insufficient.

Glibenclamide binds to the sulfonylurea receptor on pancreatic β‑cells, closing ATP‑sensitive potassium channels. This depolarises the cell, opens calcium channels, and triggers insulin release, thereby lowering circulating glucose levels.

The dose of Liamid is individualized by the prescribing clinician based on the patient’s glycaemic status, renal function, and response to therapy. The prescriber determines the starting dose and any subsequent adjustments.

Safety of glibenclamide in pregnancy and lactation has not been conclusively established. Women who are pregnant, planning pregnancy, or breastfeeding should discuss potential risks and alternatives with their healthcare provider.

To order Liamid, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Liamid (glibenclamide) belongs to the sulfonylurea class, which directly stimulates insulin secretion. Compared with metformin, which reduces hepatic glucose production, glibenclamide provides a rapid insulin‑dependent effect but carries a higher risk of hypoglycaemia, especially in renal impairment or the elderly.

Liamid tablets should be stored at room temperature, below 25 °C, in the original container to protect them from moisture and light. Keep the product out of reach of children and avoid storing in damp or excessively hot environments.

Liamid is taken orally, usually with breakfast or the first main meal of the day. The tablet should be swallowed whole with a glass of water and not crushed or chewed unless otherwise directed by a healthcare professional.

The most serious risks include severe hypoglycaemia, which can cause loss of consciousness or seizures, and rare allergic reactions such as Stevens‑Johnson syndrome. Patients should be educated to recognise early signs of low blood sugar and seek prompt medical attention for any severe skin reactions.

Liamid is contraindicated in individuals with a known hypersensitivity to sulfonylureas, in patients with type 1 diabetes, diabetic ketoacidosis, or severe hepatic or renal impairment. It should also be avoided in patients taking other insulin‑secretagogue agents without careful medical supervision.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Glibenclamide

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT